159 115

Cited 0 times in

경구 C형 간염 치료제를 이용한 만성 C형 간염의 치료

Other Titles
 Treatment of Chronic Hepatitis C Using Newly Developed Oral Antiviral Agents 
Authors
 이혜원  ;  정규식  ;  안상훈 
Citation
 Korean Journal of Medicine, Vol.88(6) : 635-642, 2015 
Journal Title
 Korean Journal of Medicine 
ISSN
 1738-9364 
Issue Date
2015
Keywords
Chronic hepatitis C ; Direct acting antivirals ; Peginterferon
Abstract
Standard care for chronic hepatitis C has been a combination of pegylated interferon-alpha and ribavirin, although this treatment has suboptimal antiviral efficacy and significant adverse events. The hepatitis C virus treatment landscape has been transformed recently by the development of direct-acting antiviral agents (DAAs) that target NS3 protease, NS5A protein, and NS5B polymerase. Several DAAs showed potent antiviral activity leading to increased rates of sustained virological response (SVR), even in difficult-to-treat patients such as older patients and those with advanced liver disease and prior failed peg-interferon/ribavirin treatment. Use of multiple DAAs without pegylated interferon has shown dramatically high SVR rates (up to nearly 100%) with negligible side effects. Interferon-free regimens are close to becoming the new standard of care for patients with chronic hepatitis C in USA and Europe. Similarly, several DAAs are near clinical use in Korea. This review discusses DAAs that have been approved or are under investigation for approval in Korea
Files in This Item:
T999900048.pdf Download
DOI
10.3904/kjm.2015.88.6.635
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
Lee, Hye Won(이혜원) ORCID logo https://orcid.org/0000-0002-3552-3560
Jung, Kyu Sik(정규식)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/163610
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse